StoneX Group’s VYNE Therapeutics VYNE Stock Holding History

StoneX Group’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-769	Closed	-$2.08K	–	690
2022 Q4	$2.08K	Buy	+769	New	+$3.07K	﹤0.01%	534

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

StoneX Group's VYNE Position: Q1 2023 in Review

StoneX Group sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 769 shares — an estimated $2.08K sold.

StoneX Group first reported a position in VYNE in Q4 2022 and held it in 1 quarter. The position peaked at $2.08K in Q4 2022. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

StoneX Group reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 769 VYNE Therapeutics shares in Q1 2023, an estimated $2.08K.
StoneX Group first reported a position in VYNE Therapeutics in Q4 2022 and held it in 1 quarter.
StoneX Group's VYNE Therapeutics position peaked at $2.08K in Q4 2022.
23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.